MEF2C-MYOCD and leiomodin1 suppression by miRNA-214 promotes smooth muscle cell phenotype switching in pulmonary arterial hypertension by Sahoo, Sanghamitra et al.
MEF2C­MYOCD and leiomodin1 
suppression by miRNA­214 promotes 
smooth muscle cell phenotype switching 
in pulmonary arterial hypertension 
Article 
Published Version 
Creative Commons: Attribution 4.0 (CC­BY) 
Open access 
Sahoo, S., Meijles, D. N., Al Ghouleh, I., Tandon, M., 
Cifuentes­Pagano, E., Sembrat, J., Rojas, M., Goncharova, E. 
and Pagano, P. J. (2016) MEF2C­MYOCD and leiomodin1 
suppression by miRNA­214 promotes smooth muscle cell 
phenotype switching in pulmonary arterial hypertension. PLoS 
ONE, 11 (5). e0153780. ISSN 1932­6203 doi: 
https://doi.org/10.1371/journal.pone.0153780 Available at 
http://centaur.reading.ac.uk/65750/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
Published version at: http://dx.doi.org/10.1371/journal.pone.0153780 
To link to this article DOI: http://dx.doi.org/10.1371/journal.pone.0153780 
Publisher: Public Library of Science 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
RESEARCH ARTICLE
MEF2C-MYOCD and Leiomodin1 Suppression
by miRNA-214 Promotes Smooth Muscle Cell
Phenotype Switching in Pulmonary Arterial
Hypertension
Sanghamitra Sahoo1,2, Daniel N. Meijles1,2¤, Imad Al Ghouleh1,2, Manuj Tandon1,
Eugenia Cifuentes-Pagano1,2, John Sembrat2,3, Mauricio Rojas2,3, Elena Goncharova2,3,
Patrick J. Pagano1,2*
1 Department of Pharmacology and Chemical Biology University of Pittsburgh, Pittsburgh, Pennsylvania,
15261, United States of America, 2 Vascular Medicine Institute, University of Pittsburgh, Pittsburgh,
Pennsylvania, 15261, United States of America, 3 Division of Pulmonary, Allergy and Critical Care Medicine,
University of Pittsburgh, Pittsburgh, Pennsylvania, 15261, United States of America
¤ Current address: Institute of Cardiovascular and Metabolic Research, University of Reading, Whiteknights,
Reading, RG6 6AS, United Kingdom
* pagano@pitt.edu
Abstract
Background
Vascular hyperproliferative disorders are characterized by excessive smooth muscle cell
(SMC) proliferation leading to vessel remodeling and occlusion. In pulmonary arterial hyper-
tension (PAH), SMC phenotype switching from a terminally differentiated contractile to syn-
thetic state is gaining traction as our understanding of the disease progression improves.
While maintenance of SMC contractile phenotype is reportedly orchestrated by a MEF2C-
myocardin (MYOCD) interplay, little is known regarding molecular control at this nexus.
Moreover, the burgeoning interest in microRNAs (miRs) provides the basis for exploring
their modulation of MEF2C-MYOCD signaling, and in turn, a pro-proliferative, synthetic
SMC phenotype. We hypothesized that suppression of SMC contractile phenotype in pul-
monary hypertension is mediated by miR-214 via repression of the MEF2C-MYOCD-leio-
modin1 (LMOD1) signaling axis.
Methods and Results
In SMCs isolated from a PAH patient cohort and commercially obtained hPASMCs exposed
to hypoxia, miR-214 expression was monitored by qRT-PCR. miR-214 was upregulated in
PAH- vs. control subject hPASMCs as well as in commercially obtained hPASMCs exposed
to hypoxia. These increases in miR-214 were paralleled by MEF2C, MYOCD and SMC con-
tractile protein downregulation. Of these, LMOD1 and MEF2C were directly targeted by the
miR. Mir-214 overexpression mimicked the PAH profile, downregulating MEF2C and
LMOD1. AntagomiR-214 abrogated hypoxia-induced suppression of the contractile
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Conclusions
Our findings illustrate a key role for miR-214 in modulation of MEF2C-MYOCD-LMOD1 sig-
naling and suggest that an antagonist of miR-214 could mitigate SMC phenotype changes
and proliferation in vascular hyperproliferative disorders including PAH.
Introduction
Pulmonary Arterial Hypertension (PAH) is a complex and progressive disease characterized
by increased lung vascular resistance and pressure, which leads to right ventricular failure and
death. A major hallmark of PAH is irreversible pulmonary arterial remodeling, manifested by
excessive cellular proliferation, apoptotic resistance and abnormal contractile-to-synthetic vas-
cular smooth muscle cell (VSMC) phenotype switching[1–3]. Sustained VSMC de-differentia-
tion underlies a characteristic vascular proliferative phase in PAH, which propagates vessel
wall occlusion. Although diverse environmental signals including sustained hypoxia and alter-
ations in extracellular matrix are known to regulate SMC phenotype [4–6], the mechanisms
that control SMC de-differentiation are not well understood.
Myocardin (MYOCD), a SMC-restricted transcriptional coactivator of serum response fac-
tor (SRF), physically interacts with SRF and selectively induces expression of all hallmark
CArG-dependent SMC marker genes, including smooth muscle-actin (SMA), SM-myosin
heavy chain (MYH11), SM22, and calponin1 (CNN1) [7–12]. The molecular basis of
MYOCD-induced transcriptional activation is complex involving additional regulation via
myocyte enhancer factor 2C (MEF2C)[13] which serves as upstream coordinator of SMC dif-
ferentiation, i.e. the contractile phenotype[14].
The VSMC contractile state is characterized by expression of SMC-specific genes, i.e.
MYH11, smoothelin, CNN1 among others controlled by MYOCD [7–12,15]. Leiomodin1
(LMOD1) is a recently described SMC-restricted gene transcriptionally regulated by MYOCD
and, similar to other MYOCD-regulated genes, LMOD1 is expected to play a fundamental role
in SMC contractility [16]. Despite the importance of MEF2C-MYOCDmodulation in SMC
phenotype switching, incomplete knowledge of MEF2C, MYOCD and SMC-specific proteins
in PAH limits our understanding of the underlying mechanisms controlling differentiation.
Epigenetic regulation by microRNAs (miRs) has garnered significant intrigue in recent
years. Short non-coding RNAs that regulate gene expression through translational repression
or degradation of mRNA[17], miRs increasingly are shown to play a role in cardiovascular
physiology and pathophysiology[18], including PAH[19,20]. A number of miRs, such as miR-
21[21] and miR-143/145[19,22], have been shown to modulate smooth muscle cell phenotype
and proliferation. The miR and mechanisms, however, involved in the control of MEF2C--
MYOCD and LMOD1-mediated SMC remodeling are unknown. miR-214, a member of the
miR-199a-214 cluster, is implicated in cancer progression[23], skeletal muscle differentiation
[24,25], ischemia injury[26], mitochondrial fatty acid oxidation[27], and failing human hearts
[28]. In the vasculature, expression of miR-214 is ubiquitous [29], but its role in phenotype
control is entirely unexplored.
In the current study, we explored the potential for miR-214 to alter SMC phenotype at mul-
tiple levels, i.e. MEF2C, MYOCD and LMOD1 expression. Herein, we demonstrate that lung
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explant-derived human PAH-PASMC and control hPASMC exposed to chronic hypoxia
exhibited markedly upregulated miR-214. This coincided with attenuated MEF2C expression,
marked decreases in MYOCD, LMOD1, MYH11, smoothelin and CNN1, and increased cell
proliferation, all of which were abrogated by anti-miR-214. Thus, we propose a novel mecha-
nism directly linking miR-214 in a pleiotropic suppression of SMC differentiation.
Method
A full methods section is available in the supplement file (See S1 File for more details).
Human Samples
The study was approved by the University of Pittsburgh Institutional Review Board and written
informed consent was obtained from all participating individuals. Lung and Pulmonary Artery
(proximal/second branch) tissues from non-diseased subjects and idiopathic PAH patients
undergoing lung transplant were provided by the PACCM Bio-Bank under protocols approved
by the University of Pittsburgh Institutional Review Board. Pulmonary artery smooth muscle
cells (hPASMCs) from non-diseased rejected transplants and PAH explants (henceforth desig-
nated as “non-PAH controls” and “PASMCs derived from PAH patients”) were isolated and
characterized as described previously[30]. Each experiment was repeated using primary (pas-
sages 3–8) hPASMCs from at least three non-PAH and PAH subjects.
Cell Culture
Human pulmonary artery smooth muscle cells (hPASMC) were purchased from Lonza (Walk-
ersville, MD) and are hereafter designated as “control PASMCs”. All hPASMCs were cultured
in growth media SmGM-2 (Lonza) in 5% fetal bovine serum (FBS). The media was reduced to
0.2% FBS for serum deprivation. Cells were grown to*80–90% confluence, and then subjected
to normoxia (21% O2, 5% CO2, balance N2) or hypoxia (1% O2, 5% CO2, balance N2) as we
described previously [31]. HEK293 cells were grown in DMEM supplemented with 10% FBS
(Gibco, Carlsbad, CA).
Oligonucleotide Transfection
Transfections with miR-214 mimic, anti-miR-214 (miR-214 antagomiR) or scrambled control
(Invitrogen Inc.) at a final concentration of 50nmol/L were performed using Lipofectamine
2000 reagent following the manufacturer’s recommendations.
Quantitative Reverse Transcriptase—PCR
Total RNA was extracted from human lung tissues and hPASMC by using miRNeasy Mini kit
(Qiagen). For RT-PCR, total RNA was reverse transcribed to cDNA by using Superscript III
(Invitrogen Inc.) following the manufacturer’s protocol. For microRNA and gene expression
analysis, we used Taqman probe and primer sets available from Invitrogen Inc. RNU43 were
used as internal control for the expression of miR-214 in human samples. mRNA expression of
all genes included in this study are relative to 18s and the results are presented as fold changes
in gene expression calculated using the 2-ΔΔ ct method.
Luciferase Reporter Assay
The constructs containing 3’ untranslated region (3’-UTR) of LMOD1 andMEF2C, including
the putative miR-214 binding sequence cloned into a luciferase reporter was obtained from
Switchgear Genomics™, and GeneCoepia™, respectively. To test the binding specificity, miR-214
miR-214 in Pulmonary Arterial Hypertension
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binding sites in the luciferase constructs of both LMOD1 (2 sites) and MEF2C (1 site) were
mutated using the Site-Directed Mutagenesis Kit (Agilent Technologies). For the two different
miR-214 binding sites on LMOD1 3’UTR, we generated plasmid constructs containing both a
single-site mutant as well as one carrying mutations on both the binding sites (double mutant).
For luciferase reporter assay, cells (HEK293 or hPASMCs) were seeded in 24-well plates and co-
transfected with 3’-UTR reporter plasmid (wildtype or mutants), and miR-214 mimic or non-
targeting mimic control. hPASMCs were transfected using Cytofect ™ Smooth Muscle Transfec-
tion kit, (Cell Applications, Inc.). Forty-eight hours after transfection, Luciferase Assay Reagent
was added to measure luciferase activity.
Statistical Analyses
Data are expressed as mean ± SEM, and for comparison of results between two data sets, an
unpaired Students’ t test was performed. One-way ANOVA followed by Bonferroni multiple
comparison tests were used for comparison of results among more than two groups using
Graphpad Prism software (version 5.04). p<0.05 was considered statistically significant.
Results
LMOD1, MYOCD &MEF2C Expression are Downregulated in PAH
Similar to contractile proteins under the direct transcriptional activation of MYOCD and
their diminished presence in vascular remodeling, we hypothesized that LMOD1 expression
would be attenuated in human PAH. To test this, we first sought to determine the levels of
expression of LMOD1 in human lungs, PA and hPASMCs derived from PAH patients.
Immunofluorescence (IF) revealed that LMOD1 was exclusively expressed in the media of
PAs from control human lungs, and its expression was decreased in the PAH cohort (Fig
1A). Western blot of lung homogenates showed expression was attenuated ~ 50% in PAH
(Fig 1B). IF and Western blot of PA isolated from human lungs (Fig 1C and 1D) further sup-
ported our observation that LMOD1 is expressed exclusively in the media and significantly
attenuated in PAH patients vs. controls. To interrogate these findings at the cellular level, we
examined LMOD1 in primary hPASMCs isolated from non-PAH controls vs. PAH patients.
LMOD1 was significantly suppressed in hPASMC from PAH patients (Fig 1E). These results
demonstrate that expression of LMOD1, a SMC-specific contractile protein, is attenuated in
human PAH.
An established regulator of LMOD1, we concomitantly investigated the expression of
MYOCD. Western blot showed that MYOCD was attenuated in isolated PAs as well as in
hPASMCs from PAH vs. non-PAH subjects (Fig 1D and 1E, respectively). To determine
whether MEF2C, a modulator of MYOCD, is aberrantly expressed during PAH, we investi-
gated the expression of MEF2C in hPASMCs from non-PAH and PAH subjects. Western blot
analysis showed that MEF2C protein was markedly attenuated (>60%) in hPASMCs from
PAH patients vs. controls (Fig 1F). qRT-PCR data showed that mRNA expression of MEF2C,
MYOCD, LMOD1, MYH11, smoothelin and CNN1 was significantly attenuated in PAs of
PAH patients (S1A–S1F Fig). Furthermore, IF analysis on vessel wall of lung sections of PAH
and non-PAH patients showed thickening of the medial layer with PAH, suggesting extensive
vascular remodeling (S2A Fig). There is a decreased expression of LMOD1 and smooth muscle
α-actin, and both proteins co-localized in the medial layer (S2A Fig). Similar to LMOD1 and
smooth muscle α-actin, smoothelin expression was also downregulated in the media of PAs of
PAH compared to non-PAH subject lung sections (S2B Fig).
miR-214 in Pulmonary Arterial Hypertension
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Fig 1. Contractile proteins, leiomodin1 (LMOD1), myocardin (MYOCD) andMEF2C are downregulated in
pulmonary artery smoothmuscle cells (hPASMCs) in pulmonary arterial hypertension (PAH). (A,B)
LMOD1 expression in lungs from PAH and non-PAH patients (n = 3) was determined by immunofluorescence
andWestern blot. Images from lung sections showed a marked decrease in LMOD1 expression (red
fluorescence) in the vessel wall, primarily the media, of PAH samples compared to non-PAH group; DAPI
nuclear staining (blue), (A). Western blot analysis of total lung homogenates showed a significant decrease in
LMOD1 expression in PAH compared to control lung homogenates (B). (C-D) LMOD1 expression in the
pulmonary artery (PA) from PAH and non-PAH patients (n = 3) was determined using immunofluorescence and
Western blot analysis, respectively. Immunofluorescence images from PA sections of non-PAH samples
showed expression of LMOD1 specific to the medial layer (smooth muscle layer, red fluorescence). LMOD1
expression was significantly attenuated in PAH samples compared to non-PAH group (C). Western blot
analysis of total PA homogenates showed significant decreases in myocardin (MYOCD) and LMOD1
expression in PAH compared to non-PAH tissue homogenates (D). Western blot analysis of PASMCs-derived
from PAH and non-PAH subjects showed decreased levels of MYOCD and LMOD1 protein in PAH group
compared to non-PAH group (n = 3–5) (E). Western blot analysis of PASMCs-derived from PAH and non-PAH
patients showed decreased levels of MEF2C protein in the PAH group compared to non-PAH subjects (n = 4)
(F). Blots are representative; graphs depict mean ± SEM (*, p<0.05).
doi:10.1371/journal.pone.0153780.g001
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miR-214, a Potential Regulator of LMOD1 and MEF2C, is Upregulated in
Human PAH and Experimental PAH
We next sought to identify novel miRs that could be involved in the regulation of smooth mus-
cle de-differentiation. Using Ingenuity Pathway Analysis (IPA), we discovered a strong associa-
tion among pulmonary hypertension, MEF2C, LMOD1, and miR-214 (Fig 2A). To interrogate
the validity of miR-214 as a phenotypic modulator, we first employed qRT-PCR to determine
the expression of miR-214 in hPASMCs from non-PAH and PAH subjects. As shown in Fig
2B, miR-214 expression was increased ~1.6-fold in SMCs isolated from PAH patients
Fig 2. miR-214 is significantly upregulated in PAH. (A) Integrated Pathway Analysis (IPA) shows potential
association between miR-214-MEF2C-LMOD1 in PAH, and other genes unique to PAH potentially
associated with miR-214. Relationships between molecules are represented as follows: bold line, direct
interaction; dotted line, indirect interaction; line with arrowhead, represents directionality of interaction;
SCN5A, sodium channel, voltage gated, type V alpha subunit; NPPA, natriuretic peptide A; NPPB, natriuretic
peptide B; NOS3, nitric oxide synthase, endothelial; BDNF, brain-derived neutrotrophic factor; SP7, Sp7
transcription factor; H2O2, hydrogen peroxide; MEF2C, myocyte enhancer factor 2C; MYOCD, myocardin;
LMOD1, leiomodin1. (B) miR-214 expression is increased (~1.6-fold) in SMC-derived from PAH patients
compared to controls subjects as measured by q-RT PCR (n = 7–8). (C) Serum-deprived control PASMCs
were exposed to normoxia (21%O2) or hypoxia (1% O2) for 24 hrs and, miR-214 expression determined by q-
RT PCR. Hypoxia resulted in significant increase in miR-214 expression in PASMCs compared to normoxic
controls (n = 8). Graphs represent mean ± SEM. *, p<0.05 versus respective control.
doi:10.1371/journal.pone.0153780.g002
miR-214 in Pulmonary Arterial Hypertension
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compared to non-PAH controls. We investigated miR-214 expression in cultured hPASMCs
(Lonza) exposed to hypoxia (known to mimic clinical features of PAH). miR-214 was signifi-
cantly upregulated in hPASMCs exposed hypoxia vs. normoxia (Fig 2C).
MEF2C and LMOD1 are Novel Direct Targets of miR-214
We applied TargetScan™ prediction algorithms to explore whether miR-214 could act as a regula-
tor of LMOD1 andMEF2C. As shown in Fig 3A, we identified miR-214 putative binding sites
(bp 95–101; bp 662–668) in the 3’UTR of LMOD1 gene, and one in MEF2C (bp 4296–4302).
Fig 3. LMOD1 andMEF2C are validated as a direct target of miR-214. (A) miR-214 binding sites in the 3’-
UTR of LMOD1 and MEF2C transcripts. Seed and target sequences are in blue, and base-pairing between
miR-214 and target site marked by vertical lines. Mutations in the reporter plasmid construct are indicated in red
letters. The double mutant (not shown) carries mutations to both sites in the 3’UTR construct vs. the single site
mutants shown in 3A. (B-E) For luciferase assays, HEK293 cells (B, D) or hPASMCs (C, E) were transfected
with miR-214 mimic or non-targeting mimic control and wildtype vs. mutant constructs for LMOD1 (B, C) or
MEF2C (D, E). Relative luciferase activities were determined 48 hrs post transfection. (n = 3–5), $, p<0.05WT
scrmb vs. mimic; *, p<0.05WTmimic vs. mutants mimic.
doi:10.1371/journal.pone.0153780.g003
miR-214 in Pulmonary Arterial Hypertension
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Both LMOD1 andMEF2C 3’UTRs display complete 7-bp complementarity to the seed region of
miR-214, and these are conserved among human, mouse, rat and other vertebrates (Targetscan
ver 6.0; S3 Fig). To determine whether the negative regulatory effects of miR-214 on LMOD1
andMEF2C expression were mediated through binding of miR-214 to the predicted sites in their
respective 3’UTRs, we performed miR-target reporter assay using a chimeric construct contain-
ing the 3’UTR downstream of the luciferase ORF in HEK293 cells. Indeed, for both LMOD1 (Fig
3B) and MEF2C (Fig 3D), a marked reduction (~75%) in luciferase activity in cells transfected
with miR-214 mimic compared to non-targeting control was observed. Further, we constructed
mutants of the 3’UTR reporter by mutating either or both miR-214 binding sites on the LMOD1
3’UTR (single-site or double mutants) as well as the singular site on MEF2C 3’UTR. Luciferase
reporter assay performed in both HEK293 (Fig 3B and 3D) and hPASMCs (Fig 3C and 3E) dem-
onstrated that loss of binding sites on the 3’UTR abrogated the effect of miR-214 mimic. Interest-
ingly, it also shows that the miR-214 binding site further from the 3’ region of LMOD1 gene (site
2) is only partially capable of rescuing the effect of miR-214, suggesting a stronger effect of miR-
214-mediated suppression via site 1 on LMOD1 3’UTR. These results establish that miR-214
interacts with the LMOD1 andMEF2C 3’UTR exerting post-transcriptional gene regulation.
miR-214 Negatively Regulates the Expression of MEF2C and Smooth
Muscle Cell Contractile Genes
The abovementioned results illustrate that miR-214 is upregulated in human PAH and hyp-
oxia, and previous reports demonstrate that contractile genes are downregulated in response to
environmental factors and diseases [1,32], leading to profound cellular changes. To recapitulate
the hypoxia-driven SMC phenotypic changes and validate the predicted role of miR-214, we
performed gain- and loss-of-function experiments interrogating the expression of SMC con-
tractile proteins, which might be modulated in PAH. Under normoxic conditions, overexpres-
sion of miR-214 in hPASMCs with miR-214 mimic reduced MEF2C and MYOCD expression
by ~30% compared to scrambled control (Fig 4A and 4B). Furthermore, nearly 50–70% reduc-
tion of LMOD1, MYH11 and smoothelin protein was observed in hPASMCs transfected with
mimic (Fig 4C–4E). Expression of CNN1 protein was reduced by ~30% compared to scram-
bled control upon overexpression of miR-214 mimic (Fig 4F).
To examine whether miR-214 antagonism is able to reverse the hypoxia-induced pheno-
typic switching, we transfected hPASMCs with antagomiR (anti-miR-214). As illustrated in Fig
5A and 5B, exposing hPASMCs to hypoxia significantly reduced expression of MEF2C and
MYOCD by ~50% while transfection with anti-miR-214 reciprocally reversed the hypoxia-
induced downregulation. Further, hypoxia significantly reduced expression of SMC-specific
contractile gene, LMOD1, by ~50% and loss-of-function with anti-miR-214 completely
reversed the hypoxia-induced LMOD1 downregulation (Fig 5C). As MYH11, smoothelin and
CNN1 are under the control of MEF2C and MYOCD, we interrogated changes in their expres-
sion in response to miR-214. Hypoxia reduced MYH11 (~50%), smoothelin (~30%) and
CNN1 (~50%) expression, and anti-miR-214 reversed this suppression (Fig 5D–5F). In the
case of smoothelin, reversal exceeded baseline control levels, suggesting that miR-214 might
play a role in regulating basal expression. In aggregate, these results suggest that miR-214
directly modulates contractile protein expression at the level of LMOD1, in addition to
upstream disruption of MEF2C-MYOCD signaling.
miR-214 Promotes Hypoxia-Induced Smooth Muscle Cell Proliferation
Dysregulation of SMC proliferation is central to the pathogenesis of PAH, and it is widely
accepted that a terminally differentiated SMC exhibits decreased proliferative potential[1]. To
miR-214 in Pulmonary Arterial Hypertension
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determine whether miR-214 participates in the induction of hPASMC proliferation, we
explored the potential for a reduced proliferative capacity of SMC transfected with anti-miR-
214 under hypoxic conditions. Consistent with previous reports, we found that hypoxia signifi-
cantly induced hPASMC proliferation (~1.5-fold vs. normoxia) as measured by Trypan blue
exclusion (Fig 6A), cell cycle progression (Fig 6B), and BrdU incorporation (S4 Fig) methodol-
ogies. Further, miR-214 antagomiR significantly attenuated hypoxia-induced hPASMC prolif-
eration (Fig 6A and 6B & S4 Fig). Because proliferation of cells is dependent on cell cycle re-
entry, we sought to determine whether progression of cells from G1/G0 to S-phase is modu-
lated by miR-214 in response to hypoxia. Western blot analysis revealed that hypoxia signifi-
cantly attenuated the expression of p21cip (~50% less), an effect which was abrogated in
hPASMC treated with anti-miR-214 (Fig 6C). Taken together, these data suggested that under
hypoxic conditions, miR-214 promotes transition into S and G2/M for which p21cip inhibition
is permissive [33]. To test this further, we investigated whether over expression of miR-214
Fig 4. miR-214 regulates expression of SMC contractile genes.HPASMCs were transfected with miR-
214 (Mimic) or scrambled control (Scrmb) under normoxic conditions for 72 hrs and lysed for Western blot
analysis. Overexpression of miR-214 using its mimic significantly decreased the expression of MEF2C (A),
MYOCD (B), LMOD1 (C), MYH11 (D), smoothelin (E), CNN1 (F), (n = 4–9). Graphs represent mean ± SEM
(*, p<0.05, **, p<0.01, ***, p<0.001).
doi:10.1371/journal.pone.0153780.g004
miR-214 in Pulmonary Arterial Hypertension
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drives proliferation by examining SMC number and cell cycle progression. When compared
with control, hPASMCs treated with miR-214 mimic showed a higher cell number (~1.5-fold
more) (Fig 6D) and greater cell cycle progression into S and G2/M phases (Fig 6E). This
response is replicated in cells from PAH vs. non-PAH subjects, (2-fold rise; S5 Fig).
Fig 5. Inhibition of miR-214 restores expression of SMC contractile proteins.HPASMCs transfected with anti-miR-214
or scrambled control (Scrmb) were exposed to normoxia (open bars) or hypoxia (filled bars) for 24 hrs and lysed for Western
blot. Hypoxia significantly decreased the expression of contractile proteins, while transfection with anti-miR-214 significantly
reversed the hypoxia-induced suppression of contractile proteins, MEF2C (A), MYOCD (B), LMOD1 (C), MYH11(D),
smoothelin (E) and CNN1 (F), (n = 3–6). Graphs represent mean ± SEM (*, p<0.05, **, p<0.01, ***, p<0.001).
doi:10.1371/journal.pone.0153780.g005
miR-214 in Pulmonary Arterial Hypertension
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Fig 6. miR-214 regulates hypoxia-induced proliferation and cell cycle progression of hPASMCs. HPASMCs transfected
with anti-miR-214 or scrambled control (Scrmb) were exposed to normoxia (open bars) or hypoxia (filled bars) for 24 hrs and
harvested for cell counting by trypan blue exclusion (A), trypsinized for flow cytometry analysis using propidium iodide staining
(B), or lysed for Western blot analysis (C). In both cell count and cell cycle analysis, hypoxia significantly increased the number
of proliferating cells and hPASMC transfected with anti-miR-214 displayed significantly attenuated hypoxia-induced
proliferation (n = 5–6). Also, hPASMC transfected with anti-miR-214 attenuated hypoxia-induced increase in S+ G2/M phase
cells as depicted by cell cycle analysis. (C) Hypoxia significantly suppressed p21cip levels in hPASMC and anti-miR-214
significantly reversed hypoxia-induced suppression of p21cip. HPASMCs were transfected with miR-214 mimic or scrambled
control under normoxic conditions for 72 hrs and harvested for cell counting by trypan blue exclusion (D), trypsinized for flow
cytometry analysis using propidium iodide staining (E). miR-214 mimic significantly increased the number of proliferating cells
and increased the number of cells in S+ G2/M phase (D, E, respectively; n = 5–6). Graphs represent mean ± SEM (*, p<0.05,
**, p<0.01, ***, p<0.001).
doi:10.1371/journal.pone.0153780.g006
miR-214 in Pulmonary Arterial Hypertension
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Inhibition of miR-214 Rescues Smooth Muscle Cell Contractile
Phenotype in PAH-PASMC
Given the aforementioned results demonstrating the effects of inhibition of miR-214 in vitro,
we investigated whether anti-miR-214 could rescue the SMC differentiated phenotype in previ-
ously de-differentiated cells from PAH patients. Indeed, antagonism of miR-214 in PAH--
PASMC reversed the depressed expression of MEF2C (Fig 7A) and LMOD1 (Fig 7B),
suggesting reversion to the contractile phenotype. Moreover, we examined the effect of miR-
214 antagonism on PAH-PASMC proliferation. Depicted in Fig 7C, antagonism of miR-214 in
Fig 7. miR-214 promotes suppression of MEF2C-LMOD1 signaling axis in PAH-PASMCs. Analysis of SMC
phenotypic markers in PASMCs derived from PAH patients (n = 3–5). PAH-PASMCs were transfected with anti-
miR-214 or scrambled control (Scrmb) and lysed for q-RT PCR andWestern blot, 72 hrs after transfection. miR-
214 antagonism in PAH-PASMCs reversed the expression of MEF2C (A) and LMOD1 (B) comparable to non-
PAH controls. (C) Analysis of proliferation in PASMCs derived from PAH patients (n = 3). PAH-PASMCs were
transfected with anti-miR-214 or Scrmb and trypsinized for cell cycle analysis 72 hrs after transfection. miR-214
antagonism in PAH-PASMCs significantly inhibited PASMC proliferation. Graphs represent mean ± SEM (*,
p<0.05, **, p<0.01, ***, p<0.001).
doi:10.1371/journal.pone.0153780.g007
miR-214 in Pulmonary Arterial Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0153780 May 4, 2016 12 / 19
PAH-PASMC is likely to explain a brake in the cell cycle progression and attenuated cell
proliferation.
Fig 8 illustrates the proposed mechanism by which PAH and hypoxia induce miR-214 and
direct (via MEF2C) phenotype change from a contractile to non-contractile, “synthetic” pro-
proliferative state.
Discussion
To our knowledge, these findings are the first to describe a complex orchestration of SMC sig-
naling and de-differentiation by miR-214 in human PAH explants and cells exposed in vitro to
hypoxia. Here, we show that miR-214 is upregulated in human PAH and controls key
upstream modulators of the differentiated contractile SMC phenotype. Hallmark identifiers of
the differentiated contractile phenotype, MEF2C, MYOCD and LMOD1 were downregulated
in human PAH and/or SMCs exposed in vitro to hypoxia. Based on a strong association of
miR-214 with MEF2C and contractile protein LMOD1 in PAH, and exact complementarity of
the miR in their 3’UTR regions, we tested miR-214’s potential synergistic role in suppressing
Fig 8. Schematic of miR-214-mediated effects on PAH-related and hypoxia-induced SMC phenotypic
modulation and de-differentiation. During vascular homeostasis, SMCs maintain a contractile/
differentiated phenotype, which changes to a pro-proliferative, synthetic or de-differentiated phenotype upon
injury. Hypoxia-induced upregulation of miR-214 exerts direct suppression both at the level of MEF2C and
LMOD1 to mediate phenotype switching and pro-proliferative response associated with vascular remodeling.
doi:10.1371/journal.pone.0153780.g008
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MEF2C (and attendant downstream contractile proteins, Fig 8) and LMOD1. Indeed, overex-
pression of miR-214 downregulated expression of MEF2C, LMOD1 and other MYOCD-regu-
lated contractile proteins, such as MYH11, smoothelin and CNN1. Reciprocally, miR-214
antagonism restored the depressed expression of MEF2C and LMOD1 (as well as other con-
tractile proteins) in SMCs subjected to hypoxia. Mutagenesis and reporter assays confirmed
that both LMOD1 and MEF2C are direct and functional targets of miR-214, binding directly to
their 3’UTR. These results together demonstrate that miR-214 directly modulates expression of
contractile protein at the level of LMOD1 as well as via upstream disruption of MEF2C--
MYOCD signaling. Intriguingly, antagonism of miR-214 also reversed hypoxia-induced sup-
pression of cell cycle inhibitor p21cip and abrogated cell proliferation. On the other hand, miR-
214 mimic promoted these processes under normoxic conditions. Finally, decreases in MEF2C
and LMOD1, and increases in proliferation of PAH patient cells were reversed by the antago-
mir. Taken together, these findings appear to advance a synergistic inhibition by miR-214 at
parallel and linear checkpoints of differentiation and propose miR-214 antagonists as a poten-
tial new therapy to mitigate PAH-related and other vasculoproliferative disorders.
The structure, function and tone of the pulmonary vascular bed depend characteristically
on the contractility of the smooth muscle cells. However, in response to a vascular injury,
SMCs undergo phenotypic switching to a de-differentiated phenotype and become prolifer-
ative [1,6]. It is broadly accepted that MYOCD, expressed specifically in cardiac and SMCs, is
the most important transcription factor necessary for activation of smooth muscle differentia-
tion. Several studies have now shown that MYOCD associates with the MADS (MCM1, Aga-
mous, Deficiens, Serum Response Factor)-box of SRF and activate expression of several critical
gene products involved in proliferation, migration and contractile function of SMCs [13,34].
Interestingly, MEF2C, another cardiac and smooth muscle-specific transcription factor shown
to be pivotal for SMC differentiation, positively regulates MYOCD [13,14,35]. Our findings
show that MEF2C and MYOCD are markedly suppressed in PAH-PASMCs. In this study, we
also provide evidence to support miR-214-mediated downregulation of MEF2C activity in
smooth muscle cells. These results are consistent with recent studies showing that knockdown
of MEF2C causes proliferation in pulmonary endothelial cells [36]. That said, future studies
could explore whether miR-214 is an important post-transcriptional regulatory control for
endothelial cells in PAH. At this juncture, it is critical to point out that, on the one hand, these
data run contrary to some of findings in the literature that imply that hypoxia can induce
MYOCD via a hypoxia response element in the MYOCD promoter [37,38]. On the other hand,
our findings are congruent with others that display precisely the opposite effect [4]. Whereas
the latter scenario of an inverse relationship between hypoxia and MYOCD would explain
SMC de-differentiation and hyperplasia in our study, the differential response across studies is
likely to be species-, tissue- and context-dependent as well as in areas of the lung more likely to
harbor progenitor cells in a hypoxic environment [39].
Leiomodin1 (LMOD1) is a novel SMC-specific gene, which is under the transcriptional reg-
ulation of MYOCD [16]. Although the precise role of LMOD1 in the physiological setting is
yet to be completely characterized, it has been implicated in SMC contractile activity and actin
cytoskeleton assembly via its association with tropomyosin [16]. Our results are the first to our
knowledge to show that LMOD1 expression is significantly attenuated both in the pulmonary
arteries and lungs, and is clinically relevant in the hPASMCs of PAH patients.
While a differentiated, contractile SMC phenotype is a critical factor in vascular homeosta-
sis, the molecular mechanisms involved in its modulation remain elusive. MEF2-dependent
transcription is known to be regulated by activators such as p38 MAP kinase[40], Ca2+/cal-
modulin kinases (CaMKs)[41], and repressors including, sumoylation[42], and histone deace-
tylases[43]. The current study is unique in showing miRNA-dependent attenuation of MEF2 in
miR-214 in Pulmonary Arterial Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0153780 May 4, 2016 14 / 19
vascular SMCs, and hence SMC phenotype modulation. Here, we demonstrate that miR-214 is
an upstream regulator of MEF2C (and by extension MYOCD) as well as LMOD1. Further, in
silico analyses using miRBase showed that miR-214 has two potential binding sites in the
LMOD1 3’-UTR, and one in the MEF2C 3’-UTR, which are conserved among humans, chim-
panzees, rhesus monkeys, rats and mice, and are broadly conserved among vertebrates.
Human miR-214 is transcribed as a member of the miR-199a-214 cluster, which, interestingly,
is regulated in a HIF1α- and/or HIF-independent manner [27]. A recent study reported miR-
214-mediated cardiac hypertrophy [44], supporting observations that miR-214 is upregulated
in heart failure patients [28,45], a negative consequence associated with PAH. Furthermore,
mice with experimental deletion of the miR-199/214 locus display defects in skeletal muscle
formation [24,46], suggesting a pivotal role of miR-214 in myogenesis. Our study, however,
provides a new perspective on the role for miR-214 in human vascular smooth muscle cell biol-
ogy. In accordance with this, we found that miR-214 is significantly upregulated in hPASMC-
derived from PAH cohort and control cells exposed to hypoxia (Fig 2B and 2C), suggesting a
critical role for miR-214 in the pathophysiological changes associated with PAH.
Although miR-214 has been shown to be involved in the regulation of multiple target genes,
such as PPARδ [27], Ncx1[26], Ezh2[25,44], ATF4[47], our findings indicate that miR-214
participates in the heretofore undescribed regulation of a MEF2C-MYOCD-contractile protein
expression pathway, which we prove to be essential for vascular homeostasis and phenotypic
modulation of SMC. As a key factor in driving SMC phenotypic changes associated with PAH,
hypoxia is known to stimulate SMC proliferation, migration, and resistance to apoptosis lead-
ing to increased medial thickening and extensive remodeling of the vessel wall [1,4]. Herein,
we show that hypoxia-mediated upregulation of miR-214 accounts for the downregulation of
SMC contractile proteins, MEF2C, MYOCD, LMOD1, MYH11, smoothelin and CNN1 in con-
trol hPASMC (Fig 5A–5F), resulting in medial thickening of the vessel wall, as is evident from
S2A Fig.
In addition, we demonstrated that hypoxia-induced SMC proliferation is attenuated by
miR-214 antagomiR. The hypoxia-induced increase in proliferation coincides with progression
of SMCs to S and G2/M phases and a concomitant decrease in G1/G0 to S-phase cell cycle pro-
gression inhibitor, p21cip (Fig 6). This suggests that miR-214 could promote SMC proliferation
by regulating cell cycle progression via targeting at a third level, cyclin-dependent kinase inhib-
itor, p21cip (Fig 8). Indeed, this assertion is supported by a recent study associating the downre-
gulation of MEF2C expression to repression of p21cip levels, thus leading to an augmentation
of cells in S phase and overall cell proliferation [48]. With that information in mind, our find-
ings suggest that PAH and hypoxia-induced upregulation miR-214 and subsequent suppres-
sion MEF2C would disinhibit p21cip. This, in turn, could be expected to release a putative
“brake” on cell cycle progression and permit SMC proliferation. Whether or not p21cip could
be more directly inhibited by miR-214 requires further study.
Furthermore, we demonstrate that ectopic increases in miR-214 in control hPASMC mim-
ics a PAH phenotype, characterized by suppression of the MEF2C-MYOCD-LMOD1 axis, as
well as other SMC-specific contractile proteins, including MYH11, smoothelin and CNN1 and,
increased hPASMC proliferation and cell cycle progression (Figs 4 and 6). Overall, we provide
strong evidence that miR-214 is important for SMC phenotype regulation in the shift from a
contractile to hyperplastic response to hypoxia and PAH.
Finally, a major highlight of the present study is the potential for miR-214 as a therapeutic
target in vascular disease. We demonstrate for the first time that inhibition of miR-214 by
exogenous administration of anti-miR-214 (miR-214 antagomiR) in hPASMC-derived from
PAH patients rescues the contractile phenotype of these cells. This is supported by increased
expression of both MEF2C and LMOD1 upon treatment of hPASMC with anti-miR-214. It
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has been shown in recent studies that miR-214 is upregulated in other cardiovascular disorders
[47], further underscoring the potential of miR-214 as a therapeutic target. That modulation of
miR-214 can singularly intervene at multiple sites in the contractile phenotype cascade (i.e.
MEF2C and LMOD1) and silence broad contractile protein expression provide a firm rationale
for it as a potential therapeutic target.
In summary, we provide compelling evidence that miR-214 plays a pivotal and pleiotropic
role in modulating SMC differentiation and proliferation by multi-tiered targeting of the
MEF2C-MYOCD-LMOD1 signaling pathway, and at the level of p21cip. Indeed, we demon-
strate PAH-induced miR-214 effects SMC de-differentiation by direct translational targeting of
LMOD1, and provide strong evidence of the same for MEF2C. Our observations indicate that
miR-214-MEF2C-LMOD1 interactions form a novel nexus of regulation of SMC phenotype
associated with PAH. They are therefore, likely to inform novel therapeutic interventions for
treatment of cardiovascular diseases including pulmonary arterial hypertension.
Supporting Information
S1 Fig. Quantitative RT-PCR analysis was performed on PA homogenates to quantify
mRNA expression.mRNA expression of MEF2C (A), MYOCD (B), LMOD1 (C), MYH11(D),
smoothelin (E) and CNN1 (F) is attenuated in PA from PAH patients compared to non-PAH
control subjects (n = 3).
(TIF)
S2 Fig. (A, B). Smooth muscle contractile proteins, LMOD1, smooth muscle α-actin and
smoothelin are downregulated within PAs of PAH lungs. LMOD1, smooth muscle α -actin
and smoothelin expression in lungs from PAH and non-PAH subjects (n = 3) were determined
using immunofluorescence (IF). Co-localization and marked decrease in LMOD1 (red) and
smooth muscle α-actin (green) expression in the vessel wall of PAH samples compared to the
non-PAH group (A). Images from lung sections also showed colocalization and reduced
expression of LMOD1 (red) and smoothelin (green) in the vessel wall of PAH samples com-
pared to the non-PAH group (B).
(TIF)
S3 Fig. miR-214 binding sites in LMOD1 and MEF2C 3’UTR are conserved among verte-
brates.
(TIF)
S4 Fig. miR-214 mediates hypoxia-induced proliferation of hPASMCs. hPASMC trans-
fected with anti-miR-214 or scrambled control were exposed to normoxia or hypoxia for 24
hrs and then lysed for BrdU incorporation assay by ELISA. Treatment with anti-miR-214 sig-
nificantly attenuated hypoxia-induced proliferation. (n = 9–12). Graphs represent
mean ± SEM (p<0.05;  p<0.01).
(TIF)
S5 Fig. Increased proliferative potential of PAH-PASMCs. Cell Cycle Analysis was per-
formed using flow cytometry assay on hPASMCs-derived from non-PAH and PAH cohorts.
The number of proliferating PASMCs was significantly higher (~1.8 fold, p<0.05) in PAH
samples compared to non-PAH subjects. (n = 3). Graphs represent mean ± SEM (p<0.05; 
p<0.01).
(TIF)
S1 File. Supplemental Information on Methods.
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